Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.2
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the three and six months ending June 30, 2023 and 2022:

Three months ended June 30, 

Six Months Ended June 30, 

    

2023

    

2022

    

2023

    

2022

Revenue

Qbrexza

$

8,079

$

6,111

$

12,173

$

13,487

Accutane

5,579

5,200

10,227

10,107

Amzeeq

1,374

1,265

2,568

4,731

Targadox

664

2,756

1,457

5,390

Ximino

155

1,035

766

2,002

Zilxi

572

555

886

1,297

Exelderm

538

1,313

1,049

2,017

Collaboration revenue

183

577

364

1,154

Revenue – related party

 

31

 

18

 

66

 

70

Other revenue

211

56

259

 

2,556

Net revenue

$

17,386

$

18,886

$

29,815

$

42,811